Agenus Target of Unusually Large Options Trading (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) saw unusually large options trading on Monday. Stock investors acquired 9,107 call options on the stock. This is an increase of 2,764% compared to the typical daily volume of 318 call options.

Agenus News Summary

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Agenus secured about $85 million in upfront gross proceeds, with up to an additional $255 million available if warrants are exercised, strengthening its balance sheet and extending its cash runway. Article Title
• Positive Sentiment: The funding is intended to advance the registrational ROBBIN Phase 3 trial of botensilimab plus balstilimab in microsatellite-stable (MSS) colon cancer, which investors appear to view as a clearer and more focused development path. Article Title
• Positive Sentiment: Management said the financing should fund operations through key clinical milestones, reducing near-term financing risk and supporting the company’s strategy shift toward neoadjuvant immunotherapy in MSS colon cancer. Article Title
• Positive Sentiment: HC Wainwright raised its price target on Agenus to $30 from $23 and reiterated a buy rating, adding to the bullish sentiment around the stock. Article Title
• Neutral Sentiment: The company is also narrowing its clinical focus by deprioritizing the BATTMAN metastatic colorectal cancer study, which may improve execution but underscores a strategic pivot away from a broader trial slate. Article Title
• Neutral Sentiment: Unusual options activity also showed a surge in call buying, suggesting traders are positioning for continued momentum. Article Title

Hedge Funds Weigh In On Agenus

Large investors have recently modified their holdings of the stock. EP Wealth Advisors LLC bought a new position in Agenus in the 4th quarter worth about $31,000. Jump Financial LLC bought a new stake in Agenus during the 2nd quarter valued at about $55,000. R Squared Ltd purchased a new position in Agenus in the fourth quarter worth about $41,000. Squarepoint Ops LLC purchased a new position in Agenus in the third quarter worth about $54,000. Finally, Redwood Family Wealth LLC purchased a new position in Agenus in the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AGEN. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright increased their price target on shares of Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research report on Tuesday, June 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $30.00.

Agenus Stock Up 83.6%

Agenus stock opened at $6.15 on Tuesday. The company has a market capitalization of $256.09 million, a P/E ratio of 3.87 and a beta of 1.55. The stock’s 50 day moving average is $3.35 and its 200 day moving average is $3.44. Agenus has a twelve month low of $2.71 and a twelve month high of $8.70.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). The company had revenue of $33.74 million for the quarter, compared to the consensus estimate of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. As a group, equities analysts expect that Agenus will post 0.02 EPS for the current year.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.